Novel compounds, pharmaceutical compositions containing same, and methods of use for same
申请人:Fasgen Inc.
公开号:EP2386550A1
公开(公告)日:2011-11-16
A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IV
wherein R21= H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, -CH2OR25, -C(O)R25, -CO(O)R25, -C(O)NR25R26, -CH2C(O)R25, or -CH2C(O)NHR25, where R25 and R26 are each independently H, C1-C10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R22 -OH, -OR27, -OCH2C(O)R27, -OCH2C(O)NHR27, -OC(O)R27, -OC(O)OR27, -OC(O)NHNH-R5, or -OC(O)NR27R28, where R27 and R28 are each independently H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R27 and R28 can each optionally contain halogen atoms; R23 and R24, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.
一种药物组合物,包括一种药物稀释剂和一种式 IV 的化合物
其中 R21= H、C1-C20 烷基、环烷基、烯基、芳基、芳烷基或烷基芳基,-CH2OR25、-C(O)R25、-CO(O)R25、-C(O)NR25R26、-CH2C(O)R25 或 -CH2C(O)NHR25,其中 R25 和 R26 各自独立地为 H、C1-C10 烷基、环烷基、烯基、芳基、芳烷基或烷基芳基,可选地含有一个或多个卤原子。R22-OH、-OR27、-OCH2C(O)R27、-OCH2C(O)NHR27、-OC(O)R27、-OC(O)OR27、-OC(O)NHNH-R5 或 -OC(O)NR27R28,其中 R27 和 R28 各自独立地为 H、C1-C20 烷基、环烷基、烯基、芳基、芳烷基或烷芳基,且 R27 和 R28 可各自任选含有卤素原子;R23和R24相同或不同,均为C1-C20烷基、环烷基、烯基、芳基、芳烷基或烷基芳基。使用此类制剂治疗癌症、减肥、治疗微生物感染、抑制神经肽-Y和/或脂肪酸合酶以及刺激CPT-1的方法。